Amgen's (AMGN) OTEZLA Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Amgen's (AMGN) OTEZLA Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

Amgen (AMGN) Misses Q1 EPS by 35c, Revenues Miss; Reaffirms FY21 EPS/Revenues Guidance

April 27, 2021 4:04 PM EDT

Amgen (NASDAQ: AMGN) reported Q1 EPS of $3.70, $0.35 worse than the analyst estimate of $4.05. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $6.25 billion.

Key results include:

Total revenues decreased 4% to $5.9 billion in comparison to the first quarter of 2020, driven by lower net selling prices, partially offset by volume... More